Significant progress made year-to-date on key clinical assets: ‐ Uliledlimab (CD73 antibody): Encouraging early results were presented at ASCO 2023 ‐...
/PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization...
- Uliledlimab is a differentiated monoclonal antibody designed to target CD73 and promote stronger activation of patients' immune system against cancer cells....
/PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization...
Award is an important victory for I-Mab and its shareholders on multiple levels, ending the multi-year long dispute Tribunal completely denied Tracon's...
Strategic reprioritization of the Company's pipeline to focus on key clinical assets and overall streamlining of corporate structure and workforce, resulting...
/PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization...
/PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization...
/PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization...
IMab Sponsored ADR (IMAB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in...